MA44873A - Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative - Google Patents

Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative

Info

Publication number
MA44873A
MA44873A MA044873A MA44873A MA44873A MA 44873 A MA44873 A MA 44873A MA 044873 A MA044873 A MA 044873A MA 44873 A MA44873 A MA 44873A MA 44873 A MA44873 A MA 44873A
Authority
MA
Morocco
Prior art keywords
exsudative
age
treatment
composition
macular degeneration
Prior art date
Application number
MA044873A
Other languages
English (en)
Inventor
Anna P Tretiakova
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA44873A publication Critical patent/MA44873A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA044873A 2016-04-15 2017-04-14 Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative MA44873A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323184P 2016-04-15 2016-04-15
US201662331100P 2016-05-03 2016-05-03
US201762442946P 2017-01-05 2017-01-05
US201762460515P 2017-02-17 2017-02-17
US201762466721P 2017-03-03 2017-03-03

Publications (1)

Publication Number Publication Date
MA44873A true MA44873A (fr) 2019-03-13

Family

ID=59253994

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044873A MA44873A (fr) 2016-04-15 2017-04-14 Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative

Country Status (10)

Country Link
US (2) US11197937B2 (fr)
EP (1) EP3452103A1 (fr)
JP (3) JP7046828B2 (fr)
KR (2) KR20230130765A (fr)
AU (1) AU2017248731A1 (fr)
CA (1) CA3019426A1 (fr)
IL (1) IL262207A (fr)
MA (1) MA44873A (fr)
SG (2) SG11201808426XA (fr)
WO (1) WO2017180936A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
WO2019079494A1 (fr) * 2017-10-18 2019-04-25 Regenxbio, Inc. Traitement de maladies oculaires et d'un cancer du côlon métastatique avec un piège à vegf avec modification post-traductionnelle humain
MX2020005451A (es) * 2017-11-27 2020-08-27 4D Molecular Therapeutics Inc Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis.
WO2019126329A1 (fr) * 2017-12-19 2019-06-27 Akouos Llc Administration d'anticorps thérapeutiques médiée par aav à l'oreille interne
US20210093734A1 (en) * 2018-02-20 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-realted macular degeneration
JP2022049718A (ja) * 2019-02-05 2022-03-30 アステラス製薬株式会社 アデノ随伴ウイルスを用いたｃｘ３ｃｌ１遺伝子の導入による網膜変性疾患の治療
WO2020206098A1 (fr) 2019-04-03 2020-10-08 Regenxbio Inc. Thérapie génique pour pathologies de l'œil
AU2020336314A1 (en) 2019-08-26 2022-04-07 Regenxbio Inc. Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab
JP2022552262A (ja) 2019-10-07 2022-12-15 リジェネックスバイオ インコーポレイテッド アデノ随伴ウイルスベクター医薬組成物および方法
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
WO2021231491A1 (fr) * 2020-05-11 2021-11-18 University Of Florida Research Foundation, Incorporated Correction de maladie par administration de vecteurs aav8 exprimant une naglu à codon optimisé
WO2021255589A1 (fr) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. Vecteur de virus adéno-associé (vaa) scfab anti-vegf et ses utilisations
WO2021255590A1 (fr) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. Vecteur de virus adéno-associé (aav) anti-vegf et ses utilisations
KR20230088630A (ko) * 2020-10-16 2023-06-20 자이로스코프 테라퓨틱스 리미티드 항-vegf 엔티티 및 음성 보체 조절인자를 코딩하는 핵산 및 연령-관련 황반 변성의 치료를 위한 그의 용도
WO2022119839A1 (fr) * 2020-12-01 2022-06-09 Akouos, Inc. Constructions d'anticorps anti-vegf et procédés associés pour le traitement de symptômes associés au neurinome de l'acoustique
US20240091380A1 (en) 2021-02-01 2024-03-21 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2023150142A1 (fr) * 2022-02-02 2023-08-10 Akouos, Inc. Constructions d'anticorps anti-vegf et méthodes associées pour le traitement de symptômes associés au schwannome vestibulaire
WO2023196873A1 (fr) 2022-04-06 2023-10-12 Regenxbio Inc. Composition pharmaceutique comprenant un vecteur de virus adéno-associé recombinant avec une cassette d'expression codant un transgène pour administration suprachoroïdienne
WO2024073669A1 (fr) 2022-09-30 2024-04-04 Regenxbio Inc. Traitement de maladies oculaires avec des vecteurs viraux recombinés codant un fab anti-vegf

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978095A1 (fr) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Transcription régulée de gènes ciblés et autres évènements biologiques
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
CA2219080A1 (fr) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Regulation d'evenements biologiques fondee sur la rapamycine
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1017829A2 (fr) 1997-08-26 2000-07-12 Ariad Gene Therapeutics, Inc. Proteines de fusion a domaine de dimerisation, de trimerisation ou de tetramerisation, et a domaine additionnel d'activation de transcription heterologue, d'inhibition de transcription, de liaison d'adn ou de liaison de ligand
IL134643A0 (en) 1997-08-27 2001-04-30 Ariad Gene Therapeutics Inc Chimeric transcriptional activators and compositions and uses related thereto
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
WO1999041258A1 (fr) 1998-02-13 1999-08-19 President And Fellows Of Harvard College Agents de dimerisation, production et utilisation
DK1916258T3 (da) 1999-08-09 2014-07-28 Genzyme Corp Forøgelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
CA2388432A1 (fr) 1999-10-21 2001-04-26 Monsanto Company Modification post-traductionnelle de proteines de recombinaison produites dans les plantes
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
CN1461342A (zh) 2000-07-26 2003-12-10 路德维格癌症研究所 糖基化vegf－b和增加可溶性vegf－b量的方法
EP1310571B1 (fr) 2001-11-13 2006-02-15 The Trustees of The University of Pennsylvania Une méthode d'identification de séquences de virus adéno-associés et kit permettant d'appliquer la méthode
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
JP2006506943A (ja) 2002-02-11 2006-03-02 ジェネンテック・インコーポレーテッド 抗原結合速度の大きい抗体変異体
US20040208847A1 (en) 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
EP2292779B1 (fr) 2003-09-30 2016-11-16 The Trustees Of The University Of Pennsylvania Variantes des virus associes aux adenovirus (AAV), sequences, vecteurs les contenant, et leur utilisation
EP2357010B1 (fr) 2005-04-07 2013-06-12 The Trustees of The University of Pennsylvania Procédé d'amélioration de la fonction d'un vecteur AAV
EP1777906A1 (fr) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Appareil de compensation d erreur d amplitude et appareil de compensation d erreur d orthogonalité
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
KR101010352B1 (ko) 2008-05-30 2011-01-25 삼성중공업 주식회사 전력 제어 장치 및 방법
AU2009313560B2 (en) 2008-11-07 2016-04-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2765755C (fr) 2009-06-17 2018-01-02 Abbott Biotherapeutics Corp. Anticorps anti-vegf et leurs utilisations
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2634253B1 (fr) 2010-10-27 2016-05-11 Jichi Medical University Virions de virus adéno-associé pour le transfert de gènes dans des cellules neuronales
EP2673289B1 (fr) 2011-02-10 2023-05-03 The University of North Carolina At Chapel Hill Vecteurs viraux à profil de transduction modifiée et procédés pour les préparer et les utiliser
BR112013021494B1 (pt) * 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
DK2699270T3 (en) 2011-04-22 2017-10-02 Univ California ADENO-ASSOCIATED VIRUS VIRUSES WITH VARIANT CAPSID AND METHODS FOR USING IT
EP2559443A1 (fr) 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et composition pharmaceutiques pour le traitement d'une maladie oculaire chez un sujet
EP3147295B2 (fr) 2011-08-24 2023-11-22 The Board of Trustees of the Leland Stanford Junior University Nouvelles protéines de capside avv pour le transfert d'acides nucléiques
US20130090375A1 (en) 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
EP2847337A4 (fr) 2012-05-09 2016-04-27 Univ Oregon Health & Science Plasmides et vecteurs viraux associés à un adénovirus
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
CN104884049A (zh) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
EP2970946A4 (fr) 2013-03-13 2016-09-07 Philadelphia Children Hospital Vecteurs viraux adéno-associés et méthodes d'utilisation associées
JP6591956B2 (ja) * 2013-03-15 2019-10-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｍｐｓ１を治療するための組成物および方法
WO2015038958A1 (fr) 2013-09-13 2015-03-19 California Institute Of Technology Récupération sélective
EP3060575B1 (fr) 2013-10-11 2018-12-05 Massachusetts Eye & Ear Infirmary Méthodes de prédiction de séquences virales ancestrales et leurs utilisations
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
EP3134431B1 (fr) 2014-04-25 2021-04-07 The Trustees Of The University Of Pennsylvania Variants de ldlr et leur utilisation dans des compositions permettant de réduire les taux de cholestérol
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EP3142750B1 (fr) * 2014-05-13 2020-07-01 The Trustees Of The University Of Pennsylvania Compositions comprenant un virus adéno-associé exprimant des constructions à double anticorps et leurs utilisations
WO2015191508A1 (fr) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Capsides chimériques
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
KR102655319B1 (ko) 2015-02-20 2024-04-04 유니버시티 오브 아이오와 리써치 파운데이션 유전적 안 질환 치료용 방법 및 조성물
CA2985081A1 (fr) * 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Expression mediee par aav d'anticorps anti-grippaux et leurs procedes d'utilisation
AU2016315703A1 (en) * 2015-08-31 2018-03-08 The Trustees Of The University Of Pennsylvania Chimeric AAV-anti-VEGF for treating cancer in canines
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
WO2017120601A1 (fr) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Méthodes et dispositifs pour le traitement de troubles oculaires postérieurs avec l'aflibercept et d'autres substances biologiques
JP2019515027A (ja) 2016-04-15 2019-06-06 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療
WO2019067540A1 (fr) 2017-09-27 2019-04-04 Regenxbio Inc. Traitement de maladies oculaires avec un fab anti-vegf à modification post-traductionnelle totalement humain
WO2020206098A1 (fr) 2019-04-03 2020-10-08 Regenxbio Inc. Thérapie génique pour pathologies de l'œil

Also Published As

Publication number Publication date
NZ746729A (en) 2023-08-25
JP2022084809A (ja) 2022-06-07
KR20190031196A (ko) 2019-03-25
US20190381194A1 (en) 2019-12-19
JP2022141856A (ja) 2022-09-29
JP7046828B2 (ja) 2022-04-04
JP7111924B2 (ja) 2022-08-02
US20220288238A1 (en) 2022-09-15
EP3452103A1 (fr) 2019-03-13
SG11201808426XA (en) 2018-10-30
IL262207A (en) 2018-11-29
AU2017248731A1 (en) 2018-10-18
JP2019518427A (ja) 2019-07-04
KR102574810B1 (ko) 2023-09-08
WO2017180936A1 (fr) 2017-10-19
SG10201913159UA (en) 2020-02-27
KR20230130765A (ko) 2023-09-12
CA3019426A1 (fr) 2017-10-19
JP7492556B2 (ja) 2024-05-29
US11197937B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
MA44873A (fr) Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3448874A4 (fr) Compositions pour le traitement de maladies
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
IL269378A (en) Optimal antibody preparations for the treatment of ocular disorders
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA47719A (fr) Esketamine pour le traitement de la dépression
MA41449A (fr) Polythérapies pour le traitement de cancers
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA41041A (fr) Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA42999A (fr) Polythérapie pour le traitement de malignités
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques